ImmuCell (ICCC) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed ImmuCell (ICCC) over the past year, gaining 116.3% versus a gain of 48.0%. ImmuCell is the larger company by market cap ($88.6 million vs $85.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | NRXS |
|---|---|---|
| Share price | $9.75 | $6.77 |
| Market cap | $88.55M | $85.02M |
| 1-day change | +0.62% | -0.88% |
| YTD return | +58.54% | +49.12% |
| 1-year return | +47.95% | +116.29% |
| 5-year return | +5.06% | — |
| P/E ratio (TTM) | 139.29 | — |
| EPS (TTM) | $0.07 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $9.33 |
| 52-week low | $4.52 | $2.21 |
| Distance from 52-week high | -19.42% | -27.44% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +62.48% |
| Average volume | 22.20K | 107.27K |
| Shares outstanding | 9.08M | 12.56M |
| Employees | 73 | 24 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed ICCC by 68.3 percentage points over the past year.
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Healthcare · Biotechnology · 73 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Healthcare · Biotechnology · 24 employees
ICCC vs NRXS FAQ
Which is bigger, ImmuCell or Neuraxis?
ImmuCell (ICCC) is larger, with a market capitalization of $88.55M compared with $85.02M for Neuraxis (NRXS).
Which stock has performed better over the past year, ICCC or NRXS?
NRXS returned +116.29% over the past 12 months, compared with +47.95% for ICCC (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Neuraxis in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.